The EBAMed team is diversified in background, knowledge, and culture to provide the broadest possible perspective. They bring together experience from different types of companies, ranging from start-ups to well established multinationals.
Our experts are creative with a track record of success in the development and global commercialization of cardiac software, medical devices and drug. They are passionate people, driven by innovation, with a clear focus on patient benefit and proving this benefit with clinical-based evidence.
The R&D team is conducted in-house, allowing it to retain greater control over its proprietary technology.
Co-Founder & Key Advisor
He received the MD degree at the University of Utah and completed an internship, residency and fellowship at Duke University, where he was on staff before coming to Mayo. His honors and awards include the ACC 2019 Distinguished Scientist Award (Translational) (2019), the Distinguished Service Award from Brigham Young University, the Haskel Schiff Award in Internal Medicine from Duke University, the Eric Prystowsky Advocate for Patients Award, and a variety of Visiting Professorship awards.
Dr. Packer is active in the Heart Rhythm Society where he is a past president and member of the Board of Trustees. He is also active in the American Heart Association and the American College of Cardiology. He has served/currently serves on editorial boards for the Circulation Arrhythmia & Electrophysiology, American Heart Journal, the Journal of Cardiovascular Electrophysiology, Heart Rhythm journal, and the (EP) Journal of the American College of Cardiology. He also has served on multiple National Heart, Lung, and Blood Institute work groups on atrial fibrillation, ablation and planning for future NIH studies.
Dr. Packer has been an active teacher and mentor, and also lectures widely on cardiac arrhythmias. He has written or co-authored more than 379 publications. He has lectured extensively in national and international meetings, giving over 1,872 invited lectures in 41 countries. He has served on the executive committee of a number of NIH multicenter randomized clinical trials, Including the MUSTT, SCD-HeFT, and HAT Trials. Dr. Packer is also the International Principal Investigator of the recently reported NIH CABANA Trial. In this capacity he led the consortium of centers directing the trial. He is the PI of the Thermedical VT Needle Electrode study, and on the Executive Committee of the LESS VT Study.
Dr. Packer is a Mayo Clinician Investigator. His translational work focuses on the mechanisms and ablation of atrial fibrillation and other cardiac arrhythmias, autologous fibroblast modulation of electrical impulse propagation in the heart, and the development of carbon particle catheter-free ablation of arrhythmias. His clinical work investigates 4/5 dimensional integrated image-guided ablation, and the development of new energy sources for the modification of cardiac tissue. His work has been funded in part by private foundations, the American Heart Association, and the NIH. A key part of his research is the development of the US Catheter Free Particle Therapy Ablation Program. He is also the PI of the Extracorporeal Particle Therapy Ablation Using Proton and Carbon Beams, that is currently under way. Dr. Packer holds US and European patents in the development of intracardiac ultrasound and 4/5D imaging, and particle therapy ablation.
Co-Founder & Key Advisor
Chief Executive Officer & Director
Chief Technology Officer
Head of R&D